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Objectives The aim of this study was to validate the Seattle Heart Failure Model (SHFM) in patients with advanced heart
failure (HF).
Background The SHFM was developed primarily from clinical trial databases and extrapolated the benefit of interventions
from published data.
Methods We evaluated the discrimination and calibration of SHFM in 445 advanced HF patients (age 52  12 years,
68.5% male, 52.4% white, ejection fraction 18  8%) referred for cardiac transplantation. The primary end point
was death (n  92), urgent transplantation (n  14), or left ventricular assist device (LVAD) implantation
(n  3); a secondary analysis was performed on mortality alone.
Results Patients were receiving optimal therapy (angiotensin-II modulation 92.8%, beta-blockers 91.5%, aldosterone
antagonists 46.3%), and 71.0% had an implantable device (defibrillator 30.4%, biventricular pacemaker 3.4%,
combined 37.3%). During a median follow-up of 21 months, 109 patients (24.5%) had an event. Although dis-
crimination was adequate (c-statistic 0.7), the SHFM overall underestimated absolute risk (observed vs. pre-
dicted event rate: 11.0% vs. 9.2%, 21.0% vs. 16.6%, and 27.9% vs. 22.8% at 1, 2, and 3 years, respectively).
Risk underprediction was more prominent in patients with an implantable device. The SHFM had different cali-
bration properties in white versus black patients, leading to net underestimation of absolute risk in blacks. Race-
specific recalibration improved the accuracy of predictions. When analysis was restricted to mortality, the SHFM
exhibited better performance.
Conclusions In patients with advanced HF, the SHFM offers adequate discrimination, but absolute risk is underestimated,
especially in blacks and in patients with devices. This is more prominent when including transplantation and
LVAD implantation as an end point. (J Am Coll Cardiol 2009;53:334–42) © 2009 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.10.023(
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she incidence and prevalence of heart failure (HF) are
ising (1,2), and these patients continue to experience poor
utcomes (3,4). Considering the high mortality rate and the
vailability of life-saving therapies like transplantation (5)
nd left ventricular assist devices (LVAD) (6,7), accurate
rognosis determination in HF is clinically important. This
s especially true because a critical mismatch between the
ecipient pool and donor organ availability persists (8), and
VAD therapy is costly with a high risk for complications
rom *Emory University, Atlanta, Georgia; and the †University of Washington,
eattle, Washington. The University of Washington owns the copyright to the Seattle
eart Failure Model. Support for this project was partially funded through an Emory
niversity Heart and Vascular Board grant entitled “Novel Risk Markers and
rognosis Determination in Heart Failure.”i
Manuscript received April 14, 2008; revised manuscript received September 16,
008, accepted October 7, 2008.9). Although peak exercise oxygen consumption remains an
mportant prognostic tool (10,11), recent data suggest an
ltered risk relationship between exercise capacity and out-
omes in the current era of HF therapy (10,12–14). Other
ultimarker risk prediction strategies (15,16) were devel-
ped in the pre–beta-blocker and defibrillator era and do
ot include the impact of medical therapy.
See page 343
The recently developed Seattle Heart Failure Model
SHFM) uses widely available clinical variables to predict
F prognosis (17) and also incorporates the impact of
herapy on outcomes. Although the model was validated on
everal cohorts, its derivation and validation were carried out
n datasets driven primarily from clinical trials that enrolled
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January 27, 2009:334–42 Seattle Heart Failure Model in Advanced HFostly white subjects and were largely conducted in an era
hen beta-blockers and defibrillators were not the standard
f care. Patient populations from clinical trials might not
eflect those with advanced HF, the group in which prog-
osis determination is arguably most important. Moreover,
he impact of contemporary therapeutic interventions in-
luding devices like defibrillators and/or biventricular pace-
akers was incorporated in the SHFM by extrapolation
i.e., by using coefficients from “external” trials). Finally,
ecent studies suggest differential effects of medical therapies
n white and black patients (18–21). In this study, we
ought to assess the performance of the SHFM in patients
ith advanced HF referred for transplant evaluation with
mphasis on the impact of device therapy and race on model
erformance.
ethods
atient population. Data on all consecutive patients
etween January 2000 and December 2006 referred for
ransplant evaluation were retrospectively abstracted to
dentify eligible patients on the basis of the following
riteria: 1) adults 18 to 70 years old; 2) ejection fraction
30% documented within 6 months of evaluation; 3)
eceiving maximum tolerated medical therapy; 4) New
ork Heart Association functional class II to IV symp-
oms; and 5) availability of at least 12 of 14 variables
omprising the SHFM within 4 weeks of evaluation.
atients with HF secondary to congenital heart disease
nd those scheduled to undergo planned cardiac surgery
ithin 6 months were excluded. A total of 445 patients
et these criteria. The institutional review board ap-
roved the study.
ata collection. Demographic and clinical information
uring the index visit was abstracted. If multiple laboratory
ata were available, values from the date closest to the date
f evaluation were used. Race was self-identified by patients,
nd race-based analyses only compared whites versus blacks.
utcomes. The primary outcome was death, urgent car-
iac transplantation (United Network for Organ Sharing
tatus 1A), or LVAD support. In both the derivation and
alidation cohorts of the original SHFM study (17), only
pproximately 2% of events were LVAD or urgent trans-
lantation as opposed to 15.6% in the current investigation.
herefore, we assessed the performance of SHFM for
ortality alone where patients undergoing urgent trans-
lantation or LVAD implantation were censored as alive at
he time of event.
HFM application. The Seattle Heart Failure Score
SHFS) was derived for all patients on the basis of the
riginal risk factor coefficients as described by Levy et al.
17). Missing covariates were replaced with the cohort mean
or score calculation. The online module, which integrates
ata from life tables for patients with 30% annual mor-
ality, was used for mean life expectancy calculations (22).
s noted by the SHFM investigators (17), the exponential cHFM equation is unsuitable for
ean life expectancy calculations
or populations with 30% an-
ual mortality, because it overes-
imates survival.
tatistical analysis. Observed
vent rates were calculated with
he Kaplan-Meier method. Pre-
icted event-free survival rates
ere obtained by the original
HFM (17):
Survival (t) exp[ t (exp[SHFS])] [1]
here t is time in years,   0.0405 (as estimated by the
HFM investigators), and SHFS is the SHFM score for
ach patient. The corresponding predicted event rates
ecome:
Event Rate (t) 1 Survival (t) [2]
Discrimination was assessed by: 1) the c-statistic, which
s equivalent to the area under the receiver-operating char-
cteristic (ROC) curve; and 2) the Royston-Sauerbrei D
tatistic. The latter is based on the variance of the linear
redictor (i.e., the score) and quantifies the prognostic
eparation that a model can provide (23). Higher values of
indicate better separation; values 1 indicate adequate
eparation (24). In addition, we calculated the false positive,
alse negative, and combined classification error rates (lo-
istic estimates) for years 1 through 5.
Calibration was assessed by: 1) the Hosmer-Lemeshow
oodness-of-fit test and graph (25); and 2) fitting the linear
redictor (i.e., the score) in an exponential survival model; a
etailed background for the latter approach is provided in
nline Appendix A. Briefly, if SHFM predictions were
trictly valid, fitting the SHFS in the validation cohort with
type-1 equation would result in a  equal to the original
.0405 and a coefficient for the SHFS equal to 1 (26,27). If
he resulting  parameter is higher than the original, survival
eclines faster than predicted and thus the original equation
eads to systematic underestimation of risk (respectively, a
ower  would point to overestimation of risk). If the
esulting coefficient for the score (i.e., the SHFS) is 1, the
riginal model predicts too low a risk for low-risk patients
nd too high a risk for high-risk patients; the opposite is
rue when the coefficient is1. In both cases, the model can
e improved by recalibration. We fitted the SHFS: 1) in the
otal cohort; 2) in patients with implantable devices versus
edically treated patients; and 3) in race-based subgroups.
n each case, we obtained estimates and standard errors for
he  parameter and coefficient of the SHFS by bootstrap-
ing (1,000 random samples) (28,29). In addition, we used
Cox-Snell-type graph to assess observed versus predicted
Abbreviations
and Acronyms
HF  heart failure
IQR  interquartile range
LVAD  left ventricular
assist device
SHFM  Seattle Heart
Failure Model
SHFS  Seattle Heart
Failure Scoreumulative hazard in the total cohort.
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Seattle Heart Failure Model in Advanced HF January 27, 2009:334–42Finally, because we detected both systematic deviation of
bserved versus predicted risk and different race-specific
oefficients for the SHFS, we proceeded to race-specific
ecalibration of the model to provide possibly more accurate
stimates (30). A detailed background for this process is
rovided in the Online Appendix A. In addition, the
pplication of the Hosmer-Lemeshow goodness-of-fit test
s further explained in the Online Appendix B. Analyses
ere performed with Stata 9.2 (StataCorp LP, College
tation, Texas). The D-statistic was calculated with a Stata
aseline Patient Characteristics
Table 1 Baseline Patient Characteristics
Variable All (n  445)
Age, yrs 52.2 12.4
Gender, % male 68.5
Race, %
White 52.4
Black 44.5
Other 3.1
Body mass index, kg/m2 29.6 7.9
Ischemic etiology, % 38.2
NYHA functional class 2.5 0.7
Left ventricular ejection fraction, % 18.2 7.9
Devices, %
Defibrillator 30.3
Biventricular pacemaker 3.4
Combined 37.3
Systolic blood pressure, mm Hg 114.2 18.7
Heart rate, beats/min 78 14
Sodium, mEq/l 137.4 3.4
Potassium, mEq/l 4.1 0.5
Creatinine, mg/dl 1.4 1
Blood urea nitrogen, mg/dl 22.7 16.4
Glucose, mg/dl 120.1 66.9
Cholesterol, mg/dl* 159.3 38.6
Uric acid, mg/dl† 8.4 0.9
Hemoglobin, g/dl 13.3 1.8
White blood cells, 103/mm3 7.5 2.2
Lymphocytes, %‡ 24.5 7.5
Albumin, g/dl§ 3.5 0.6
Comorbidities, %
Hypertension 63.0
Diabetes mellitus 39.3
Dyslipidemia 48.7
Depression 25.8
Chronic lung disease 25.3
Medications, %
ACE inhibitor or ARB 90.8
Beta-blockers 91.5
Aldosterone antagonists 46.3
Diuretics 87.8
Allopurinol 6.8
Digoxin 52.9
Statins 43.8
Antiarrhythmics 27.2Available in 401 of 445 (90.1%) patients; †available in 314 of 445 (70.6%) patients; ‡available in 406
ACE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; NYHA  New York Heartodule written by Patrick Royston, Cancer Group, MRC
linical Trials Unit, United Kingdom.
esults
aseline characteristics and outcomes. We studied 445
dvanced HF patients receiving optimal therapy (Table 1).
otal time at risk was 980 patient-years, and median
ollow-up was 21 months (25% to 75%: 10 to 37 months).
verall 92 of 445 (20.7%) patients died; annual mortality
ent (n  109) No Event (n  336) p Value
51.3 15.1 52.4 11.4 0.941
74.3 66.7 0.155
54.1 51.8 0.986
43.1 44.9
2.8 3.3
28.7 7.7 30.3 8.0 0.119
42.2 36.9 0.364
2.9 0.7 2.4 0.6 0.001
15.9 6.1 19.0 8.3 0.001
18.3 34.2 0.002
7.3 2.1 0.014
41.3 36.0 0.362
10.2 18.4 115.5 18.7 0.002
82 16 76 13 0.008
35.9 3.3 137.9 3.2 0.001
4.1 0.5 4.0 0.5 0.253
1.5 1.4 1.4 0.8 0.003
26.5 15.4 21.5 16.5 0.001
18.7 46.6 120.5 72.2 0.603
58.4 42.7 159.6 37.3 0.811
8.5 1.7 8.4 0.5 0.482
13.2 1.8 13.3 1.8 0.626
7.7 2.2 7.4 2.2 0.245
22.4 8.0 25.1 7.2 0.001
3.4 0.7 3.5 0.5 0.043
56.6 65.4 0.124
39.3 39.3 1.000
48.6 48.8 1.000
37.6 20.9 0.002
35.8 20.6 0.003
90.9 93.4 0.111
74.3 97.0 0.001
52.3 44.3 0.153
95.4 85.3 0.004
8.6 6.3 0.514
71.6 46.9 0.001
38.5 45.5 0.222
33.9 25.1 0.083Ev
1
1
1
1of 445 (91.2%) patients; §available in 429 of 445 (96.4%) patients.
Association.
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January 27, 2009:334–42 Seattle Heart Failure Model in Advanced HFas 9.4%. In addition, 14 patients underwent urgent trans-
lantation and 3 underwent LVAD implantation, resulting
n a 24.5% cumulative and 11.1% annual event rate.
The median time to LVAD implantation or transplan-
ation was 10 months, and the median SHFS for these
atients was 1.17 (interquartile range [IQR]: 0.55 to 1.54).
his was comparable to that for patients who died (1.04,
QR: 0.39 to 1.72, p  0.887) but higher than those
ithout an event (0.31, IQR: 0.19 to 0.81, p  0.001).
ctual listing for transplantation by quintile of SHFS (from
owest to highest risk) was 6.7% (n  6), 12.4% (n  11),
4.6% (n  13), 15.7% (n  14), and 21.4% (n  19),
 0.004 for linear trend.
erformance of the SHFM. Table 2 presents the observed
ersus predicted event rates. Overall the SHFM equation
nderestimated risk; the goodness-of-fit for observed versus
he SHFM-expected event rates is presented in Figure 1.
ystematic underestimation of event rates was detected,
nd the lack-of-fit attained statistical significance after
ear 2. The Cox-Snell type graph in Figure 2 shows the
iscordance between observed versus predicted cumula-
ive hazards.
he SHFM Performance for Combined End Point and Mortality Pred
Table 2 The SHFM Performance for Combined End Point and M
Combined Outcome E
Year Predicted Observed (95%
Total (n  445)
1 9.2 11.0 (08.3–14
2 16.6 21.0 (16.9–25
3 22.8 27.9 (23.0–33
4 28.2 35.7 (29.6–42
5 33.0 40.7 (33.8–48
With device (n  316)
1 9.5 13.1 (9.6–17.7
2 17.1 21.0 (16.3–27
3 23.4 27.5 (21.6–34
4 28.9 38.6 (30.5–47
5 33.7 44.9 (35.2–55
Without device (n  129)
1 8.3 6.1 (3.0–12.4
2 15.3 20.3 (13.7–29
3 21.3 28.0 (20.0–38
4 26.5 31.4 (22.6–42
5 31.2 35.4 (25.8–47
White (n  233)
1 9.7 8.6 (5.5–13.3
2 17.4 19.4 (14.3–25
3 23.9 27.4 (20.9–35
4 29.4 36.4 (28.2–46
5 34.3 41.6 (32.4–52
Black (n  198)
1 8.2 14.5 (9.9–20.9
2 15.1 24.0 (17.6–32
3 21.1 28.8 (22.0–37
4 26.4 34.0 (25.5–44
5 31.0 39.2 (29.1–51I  confidence interval; SHFM  Seattle Heart Failure Model.The SHFS achieved a likelihood ratio chi-square of 76.9
p  0.001) in the cohort when fitted in an exponential
urvival model. The  parameter, however, was higher
ompared with the original (  0.0585 vs.   0.0405,
 0.007), indicating that the original equation underes-
imated risk throughout follow-up (actual decline in event-
ree survival was faster than predicted). In the defibrillator
nd/or biventricular pacemaker subgroup,  was signifi-
antly higher (  0.0619 vs.   0.0405, p  0.013),
hereas in medically treated patients it was not different
  0.0500 vs.   0.0405, p  0.360) compared with the
riginal , indicating more prominent risk underestimation
n patients with devices.
The  parameter was similar in whites versus blacks
  0.0601 vs.   0.0597). However, there was a
ignificant modification effect of race on the coefficient of
he SHFS (0.77 in whites vs. 1.15 in blacks, p  0.010),
ointing to underestimation of high risk in blacks and low
isk in whites by the original SHFM (Fig. 3); this results in
net underestimation of absolute risk in blacks (Table 2).
The SHFM had adequate discrimination throughout the
-year period (Table 2), although c-statistics were lower in
s
ity Predictions
ate Mortality Rate
C-Statistic Observed (95% CI) C-Statistic
0.78 8.6 (6.2–11.9) 0.76
0.73 17.2 (13.5–21.9) 0.71
0.74 24.5 (10.7–30.3) 0.72
0.75 32.0 (26.0–39.0) 0.73
0.75 37.3 (30.3–45.3) 0.73
0.78 10.4 (7.3–14.8) 0.77
0.71 16.7 (12.3–22.3) 0.69
0.73 23.5 (17.8–30.7) 0.71
0.73 34.1 (26.1–43.7) 0.73
0.73 40.9 (30.9–52.5) 0.72
0.79 4.3 (1.8–10.1) 0.74
0.80 18.0 (11.7–27.1) 0.76
0.78 25.9 (18.0–36.4) 0.75
0.79 29.3 (20.7–40.6) 0.76
0.79 33.5 (23.9–45.6) 0.75
0.78 6.2 (3.7–10.5) 0.78
0.68 15.7 (11.0–22.0) 0.68
0.71 24.1 (17.7–32.2) 0.70
0.70 32.3 (24.3–42.2) 0.70
0.69 37.9 (28.6–49.0) 0.69
0.79 12.4 (8.2–18.7) 0.77
0.78 20.5 (14.6–28.5) 0.76
0.78 25.6 (18.6–34.8) 0.75
0.79 31.0 (22.6–41.6) 0.76
0.80 36.4 (26.3–48.9) 0.77iction
ortal
vent R
CI)
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Seattle Heart Failure Model in Advanced HF January 27, 2009:334–42atients with devices and in whites. Similarly, the D statistic
as 1.376 overall, 1.350 in those with a defibrillator and/or
iventricular pacemaker, 1.456 in those without devices,
.171 in whites, and 1.605 in blacks. The false-positive
lassification error rate for years 1 through 5 ranged from
0.2% to 35.3%, the false negative classification error rate
anged from 27.8% to 30.5%, and the combined error rate
anged from 29.0% to 32.9%.
Figure 1 Overall Calibration of the SHFM
Systematically lower event rates are noted for the Seattle Heart Failure Model (SH
throughout the 5-year period; the lack-of-fit attained significance after year 2. H-L 
Figure 2 Cox-Snell Type Graph
of Observed Versus Predicted Hazards
The observed (Nelson-Aalen estimate) is plotted here against the Seattle Heart
Failure Model–predicted cumulative hazard. Ideally, the observed hazard should
follow the identity line (red dashed line). There is systematic underestimation
of risk as evident from the consistently deviating observed hazard.erformance of SHFM for mortality alone. When mor-
ality alone was assessed, the SHFM exhibited better
alibration. Table 2 summarizes observed versus predicted
urvival rates. The  parameter for the SHFS was 0.0499 in
he total cohort, 0.0514 in the defibrillator and/or biven-
ricular pacemaker group, and 0.0460 in the medically
reated group; none of these was significantly different from
he original . The significant interaction with race, how-
ore-based risk categories
er-Lemeshow goodness-of-fit chi-square.
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Figure 3 Kaplan-Meier Survival Curves
for White Versus Black Patients
With the cohort median Seattle Heart Failure Model (SHFM) score (0.42) to
classify risk, low-risk blacks had a better outcome compared with low-risk
whites. In contrast, blacks with a high SHFM score had worse outcomes than
whites. The log-rank chi-square for the 4 groups was 51.2, 3 df, p  0.001.
The Mantel-Haenszel chi-square for modification effect of race on SHFM was
7.71, 1 df, p  0.005.FM) sc
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January 27, 2009:334–42 Seattle Heart Failure Model in Advanced HFver, persisted; the coefficient of the SHFS was 0.80 in
hite versus 1.10 in black patients (p  0.037). Discrimi-
ation was retained; the c-statistics for mortality prediction
ere 0.76, 0.71, 0.72, and 0.73 at 1, 2, 3, and 5 years,
espectively.
ean survival. Table 3 summarizes the observed versus
HFM-predicted mean event-free survival (primary end
oint) and mean survival.
ecalibration. The SHFM was recalibrated by: 1) adjust-
ng predicted event rates with separate correction factors, as
stimated in our cohort, for patients with a defibrillator
nd/or biventricular pacemaker versus medically-treated
atients; and 2) using race-specific coefficients (0.77 for
hites and 1.15 for blacks, as estimated in our cohort) for
he SHFS. This resulted in adequate calibration for all
roups (Fig. 4), and race-based discrepancies were resolved
bserved Versus SHFM-Expected Mean Survival
Table 3 Observed Versus SHFM-Expected Mean Survival
Population n
SHFM-
Predicted
Survival
(Yrs)
Mean Observed
Event-Free*
Survival
(Yrs)
Mean
Observed
Survival
(Yrs)
Total 445 7.5 5.9 (5.3–6.4) 6.2 (5.6–6.8)
With device 316 7.5 5.6 (5.0–6.3) 6.0 (5.3–6.6)
Without device 129 8.1 6.2 (5.4–7.0) 6.5 (5.7–7.3)
White 233 7.0 6.0 (5.3–6.8) 6.4 (5.7–7.2)
Black 198 8.0 5.7 (4.9–6.4) 5.9 (5.1–6.6)
Survival free from urgent transplantation and left ventricular assist device implantation.
SHFM  Seattle Heart Failure Model.
A
C
Figure 4 Effect of Recalibration of the SHFM on Survival Estim
After adjusting event-free survival to the cohort and with race-specific coefficients f
Heart Failure Model (SHFM) score, predictions are consistently within the 95% conFig. 5). Adjusted predictions with the web-based SHFM
odule are presented in Table 4. The recalibrated equations
nd extended prediction tables are included in the Online
ppendix.
iscussion
n this study we assessed the performance of the SHFM in
dvanced HF patients referred for cardiac transplantation
ho were racially diverse and receiving optimal contempo-
ary therapy—characteristics that set our study apart from
he original study. We found that overall the SHFM
rovided good discrimination between low- versus high-risk
atients. However, we detected that in terms of absolute risk
he model systematically overestimated survival and under-
stimated risk, an effect more pronounced among patients
ith implanted devices. Moreover, the model had differen-
ial race-based properties. These deviations in absolute risk
rediction are important when applying a model for clinical
ecision-making and suggest that recalibration might be
ecessary to improve SHFM applicability in transplant and
VAD eligible populations when the end point of interest
s survival free of LVAD or urgent transplantation.
Several explanations can be provided for the observed
igher-than-predicted event rate in our cohort. The ex-
ected benefits of medications and devices in the SHFM
ere extrapolated from clinical trials. It is well-known that,
ue to the strict enrollment criteria, subjects enrolled in
rials might not represent the patients in “real-life,” and
B
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Seattle Heart Failure Model in Advanced HF January 27, 2009:334–42herefore the observed outcomes with these interventions
ight be different in the clinical setting. Also, we specifi-
ally focused on a sicker population of patients referred for
ransplantation who might have a higher relative but lower
bsolute benefit from these interventions. We did observe
his in both medical- and device-treated patients, but it was
ore exaggerated in the subgroup with a defibrillator and/or
iventricular pacemaker. However, the model was designed
or prophylactic defibrillator use, and it is possible that a
atient who has a therapeutic indication for a defibrillator
ight be at higher risk than predicted by the model. Finally,
he deviation between observed versus expected survival
ecame more pronounced with time. This raises the ques-
ion of whether SHFM predictions should be calculated
erially as both medical therapy and physiologic measures of
isk change over time and whether the “baseline” measures
re more accurate for only short- to intermediate-term
utcomes.
The SHFM was designed to predict a death/LVAD/
rgent transplantation combined end point, the same as in
his analysis. However, 98% of the events in the original
tudy were death. This fact raises important issues. A higher
ate of LVAD implantation and/or urgent transplantation
ight lead to a higher overall event rate. Considering that
Figure 5 Recalibrated SHFM Predictions in White Versus Black
After race-specific recalibration, the Seattle Heart Failure Model (SHFM)-based eve
risk categories. The race-specific recalibration effect is exemplified here by examin
high-risk predictions.
ecalibrated 1-Year Riskredictions for the Combined End Point
Table 4 Recalibrated 1-Year RiskPredictions for the Combined End Point
SHFM-
Predicted*
White Black
Device () Device () Device () Device ()
5% 8% 6% 8% 7%
10% 13% 10% 18% 15%
15% 17% 14% 27% 22%
20% 21% 17% 35% 30%
25% 24% 20% 44% 37%
30% 28% 23% 53% 45%
eath or urgent transplantation or left ventricular assist device implantation. *Can be derived withT
ither the web-based module or the original equation.
SHFM  Seattle Heart Failure Model.ur patient population was sicker as compared with the
riginal SHFM cohort, it is not surprising that a larger
roportion of patients underwent these procedures in the
urrent study (16% vs. 2%). Thus, the miscalibration seen
ight not be due to SHFM performance but rather to the
HFM being more accurate for mortality prediction than a
ombined outcome. Indeed, when we assessed the model
erformance restricting the outcome to death alone, the
odel performance improved significantly. Unlike mortal-
ty, the timing for urgent transplantation or LVAD implan-
ation can vary between institutions and physicians. In the
urrent study, the model yielded systematic errors when
pplied to a composite end-point in which physician-
etermined components were more common. This calls for
autious use of models when predicting a composite end
oint.
Existing evidence suggests that therapies and prognostic
actors might have a differential association with outcomes in
hites versus blacks (31–33). We also observed different
ace-based prognostic properties of the SHFM score.
hether this represents an environmental or a biologic
asis is beyond the scope of this discussion but does
nderscore the fact that data generated in 1 group might not
e simply extrapolated in another. For a risk score to attain
ide use for clinical decision-making, the transportability of
bsolute risk predictions to other settings beyond where
hey were originally developed needs to be explicitly tested
34). In this aspect, recalibration of a model is important
30,35). Indeed, we showed that race-specific recalibration
ignificantly improves SHFM accuracy. It is important to
ote, however, that the recalibrated SHFM risk prediction
unctions have not been evaluated in an independent cohort.
n this study, we also demonstrated differences based not
nly on race but also on whether patients were receiving
evice-based therapy. All of these interesting and provoca-
ive results need validation in different cohorts to under-
tand their subtleties and nuances in the various groups.
ents
predictions closely follow observations in both whites and blacks and across
3-year event rates with the cohort median SHFM score to classify low- versusPati
nt rate
ing thehis can only be achieved in a timely and expedited manner
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January 27, 2009:334–42 Seattle Heart Failure Model in Advanced HFy having easier access to the existing clinical trials and
egistry databases rather than creating newer cohorts for any
iven question individually.
The observed mean life expectancy was significantly
ower than expected by the SHFM. These prediction
odels are derived to assess prognosis in populations and
ot individuals (36). However, the availability of mean life
xpectancy calculation on the basis of individual patient data
akes it lucrative to extrapolate results to individual pa-
ients. Our results underscore that caution needs to be
xercised when extrapolating results from prediction models
o individuals. There are currently no standards as to what
eviation from expected mean life expectancy (e.g., 15% or
0% around the mean) is “acceptable.”
tudy limitations. By definition we limited our study
ample to those with 2 missing variables for SHFM.
hether those patients in whom more variables were
issing simply represent a random event or specific patient
haracteristics biasing our result is not known. We also
mputed the cohort means for missing values. However,
xcept for the lymphocyte count (70.6%), all other data were
vailable on 90% of the cohort. Finally, only a minority of
atients did not have a defibrillator or a biventricular
acemaker. Although we did observe a more exaggerated
iscrepancy in prediction for device versus medical therapy-
lone patients, this might be related to the limited power to
etect difference in the medically treated group.
onclusions
ur study shows that in patients with advanced HF,
lthough the discrimination of the SHFM is comparable to
he original investigation, the model overestimates survival
specially in patients with implanted devices. Moreover, the
HFM leads to an underestimation of risk in high-risk
lack patients. Prediction models are derived for popula-
ions, and individual patient data should be reviewed with
aution. Finally, recalibration might be needed if the event
f interest is transplantation and/or LVAD implantation
ather than death.
eprint requests and correspondence: Dr. Javed Butler, Emory
niversity Hospital, 1365 Clifton Road, Suite AT430, Atlanta,
eorgia 30322. E-mail: javed.butler@emory.edu.
EFERENCES
1. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke
statistics—2007 update: a report from the American Heart Association
Statistics Committee and Stroke Statistics Subcommittee. Circulation
2007;115:e69–171.
2. Bleumink GS, Knetsch AM, Sturkenboom MC, et al. Quantifying the
heart failure epidemic: prevalence, incidence rate, lifetime risk and
prognosis of heart failure. The Rotterdam Study. Eur Heart J
2004;25:1614–9.
3. Roger VL, Weston SA, Redfield MM, et al. Trends in heart failure
incidence and survival in a community-based population. JAMA
2004;292:344–50.4. Goldberg RJ, Ciampa J, Lessard D, Meyer TE, Spencer FA. Long-
term survival after heart failure: a contemporary population-based
perspective. Arch Intern Med 2007;167:490–6.
5. Taylor DO, Edwards LB, Boucek MM, et al. Registry of the
International Society for Heart and Lung Transplantation: twenty-
fourth official adult heart transplant report—2007. J Heart Lung
Transplant 2007;26:769–81.
6. Rogers JG, Butler J, Lansman SL, et al. Chronic mechanical circula-
tory support for inotrope-dependent heart failure patients who are not
transplant candidates: results of the INTrEPID Trial. J Am Coll
Cardiol 2007;50:741–7.
7. Stevenson LW, Miller LW, Desvigne-Nickens P, et al. Left ventric-
ular assist device as destination for patients undergoing intravenous
inotropic therapy: a subset analysis from REMATCH (Randomized
Evaluation of Mechanical Assistance in Treatment of Chronic Heart
Failure). Circulation 2004;110:975–81.
8. Zaroff JG, Rosengard BR, Armstrong WF, et al. Consensus confer-
ence report: maximizing use of organs recovered from the cadaver
donor: cardiac recommendations, March 28–29, 2001, Crystal City,
Va. Circulation 2002;106:836–41.
9. Clegg AJ, Scott DA, Loveman E, et al. The clinical and cost-
effectiveness of left ventricular assist devices for end-stage heart failure:
a systematic review and economic evaluation. Health Technol Assess
2005;9:1–132, iii–iv.
0. O’Neill JO, Young JB, Pothier CE, Lauer MS. Peak oxygen consump-
tion as a predictor of death in patients with heart failure receiving
beta-blockers. Circulation 2005;111:2313–8.
1. Lund LH, Aaronson KD, Mancini DM. Validation of peak exercise
oxygen consumption and the Heart Failure Survival Score for serial
risk stratification in advanced heart failure. Am J Cardiol 2005;95:
734–41.
2. Peterson LR, Schechtman KB, Ewald GA, et al. The effect of
beta-adrenergic blockers on the prognostic value of peak exercise
oxygen uptake in patients with heart failure. J Heart Lung Transplant
2003;22:70–7.
3. Abraham WT, Young JB, Leon AR, et al. Effects of cardiac resyn-
chronization on disease progression in patients with left ventricular
systolic dysfunction, an indication for an implantable cardioverter-
defibrillator, and mildly symptomatic chronic heart failure. Circulation
2004;110:2864–8.
4. Young JB, Abraham WT, Smith AL, et al. Combined cardiac
resynchronization and implantable cardioversion defibrillation in ad-
vanced chronic heart failure: the MIRACLE ICD Trial. JAMA
2003;289:2685–94.
5. Aaronson KD, Schwartz JS, Chen TM, Wong KL, Goin JE, Mancini
DM. Development and prospective validation of a clinical index to
predict survival in ambulatory patients referred for cardiac transplant
evaluation. Circulation 1997;95:2660–7.
6. Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV.
Predicting mortality among patients hospitalized for heart failure:
derivation and validation of a clinical model. JAMA 2003;290:2581–7.
7. Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure
Model: prediction of survival in heart failure. Circulation 2006;113:
1424–33.
8. Russo AM, Hafley GE, Lee KL, et al. Racial differences in outcome
in the Multicenter UnSustained Tachycardia Trial (MUSTT): a
comparison of whites versus blacks. Circulation 2003;108:67–72.
9. Vorobiof G, Goldenberg I, Moss AJ, Zareba W, McNitt S. Effec-
tiveness of the implantable cardioverter defibrillator in blacks versus
whites (from MADIT-II). Am J Cardiol 2006;98:1383–6.
0. Taylor JS, Ellis GR. Racial differences in responses to drug treatment:
implications for pharmacotherapy of heart failure. Am J Cardiovasc
Drugs 2002;2:389–99.
1. Ghali JK, Tam SW, Ferdinand KC, et al. Effects of ACE inhibitors or
beta-blockers in patients treated with the fixed-dose combination of
isosorbide dinitrate/hydralazine in the African-American Heart Fail-
ure Trial. Am J Cardiovasc Drugs 2007;7:373–80.
2. Seattle Heart Failure Model. Available at: http://depts.washington.
edu/shfm. Accessed April 12, 2008.
3. Royston P, Sauerbrei W. A new measure of prognostic separation in
survival data. Stat Med 2004;23:723–48.
4. Royston P, Parmar MK, Sylvester R. Construction and validation of a
prognostic model across several studies, with an application in super-
ficial bladder cancer. Stat Med 2004;23:907–26.
22
2
2
2
3
3
3
3
3
3
3
K
F
r
L
342 Kalogeropoulos et al. JACC Vol. 53, No. 4, 2009
Seattle Heart Failure Model in Advanced HF January 27, 2009:334–425. Hosmer DW Jr., Lemeshow S. Applied Survival Analysis. New York:
John Wiley & Sons, 1999.
6. Harrell FE Jr., Lee KL, Mark DB. Multivariable prognostic models:
issues in developing models, evaluating assumptions and adequacy, and
measuring and reducing errors. Stat Med 1996;15:361–87.
7. van Houwelingen HC. Validation, calibration, revision and combina-
tion of prognostic survival models. Stat Med 2000;19:3401–15.
8. Efron B. Better bootstrap confidence intervals. J Am Stat Assoc
1987;82:171–85.
9. Carpenter J, Bithell J. Bootstrap confidence intervals: when, which,
what? A practical guide for medical statisticians. Stat Med 2000;19:
1141–64.
0. D’Agostino RB Sr., Grundy S, Sullivan LM, Wilson P. Validation of
the Framingham coronary heart disease prediction scores: results of a
multiple ethnic groups investigation. JAMA 2001;286:180–7.
1. Smith GL, Shlipak MG, Havranek EP, et al. Race and renal
impairment in heart failure: mortality in blacks versus whites. Circu-
lation 2005;111:1270–7.
2. Singh H, Gordon HS, Deswal A. Variation by race in factors
contributing to heart failure hospitalizations. J Card Fail 2005;11:
23–9. a3. Dunlap SH, Sueta CA, Tomasko L, Adams KF Jr. Association of
body mass, gender and race with heart failure primarily due to
hypertension. J Am Coll Cardiol 1999;34:1602–8.
4. Altman DG, Royston P. What do we mean by validating a prognostic
model? Stat Med 2000;19:453–73.
5. Liu J, Hong Y, D’Agostino RB Sr., et al. Predictive value for the
Chinese population of the Framingham CHD risk assessment tool
compared with the Chinese Multi-Provincial Cohort Study. JAMA
2004;291:2591–9.
6. Graf E, Schmoor C, Sauerbrei W, Schumacher M. Assessment and
comparison of prognostic classification schemes for survival data. Stat
Med 1999;18:2529–45.
ey Words: heart failure y prognosis y statistical models.
APPENDIX
or supplementary tables and background data for the validation and
ecalibration of the Seattle Heart Failure Model and the Hosmer-
emeshow goodness-of-fit test, please see the online version of this
rticle.
